BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 18751708)

  • 21. The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma.
    Sufan RI; Jewett MA; Ohh M
    Am J Physiol Renal Physiol; 2004 Jul; 287(1):F1-6. PubMed ID: 15180922
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and molecular characterization of Brazilian families with von Hippel-Lindau disease: a need for delineating genotype-phenotype correlation.
    Gomy I; Molfetta GA; de Andrade Barreto E; Ferreira CA; Zanette DL; Casali-da-Rocha JC; Silva WA
    Fam Cancer; 2010 Dec; 9(4):635-42. PubMed ID: 20567917
    [TBL] [Abstract][Full Text] [Related]  

  • 23. pVHL: a multipurpose adaptor protein.
    Frew IJ; Krek W
    Sci Signal; 2008 Jun; 1(24):pe30. PubMed ID: 18560019
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of novel VHL target genes and relationship to hypoxic response pathways.
    Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Richards FM; Johnson CM; Maher ER
    Oncogene; 2005 Jun; 24(28):4549-58. PubMed ID: 15824735
    [TBL] [Abstract][Full Text] [Related]  

  • 25. VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma.
    Razafinjatovo CF; Stiehl D; Deininger E; Rechsteiner M; Moch H; Schraml P
    Oncotarget; 2017 Feb; 8(6):10199-10212. PubMed ID: 28052007
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genotype-phenotype relations of the von Hippel-Lindau tumor suppressor inferred from a large-scale analysis of disease mutations and interactors.
    Minervini G; Quaglia F; Tabaro F; Tosatto SCE
    PLoS Comput Biol; 2019 Apr; 15(4):e1006478. PubMed ID: 30943211
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Cystic renal neoplasms. New entities and molecular findings].
    Moch H
    Pathologe; 2010 Oct; 31 Suppl 2():239-43. PubMed ID: 20652265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Von hippel-lindau: a tumor suppressor links microtubules to ciliogenesis and cancer development.
    Kuehn EW; Walz G; Benzing T
    Cancer Res; 2007 May; 67(10):4537-40. PubMed ID: 17510376
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones.
    Tsuchiya MI; Okuda H; Takaki Y; Baba M; Hirai S; Ohno S; Shuin T
    Oncol Rep; 2005 Jun; 13(6):1033-41. PubMed ID: 15870918
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NF-kappaB-dependent plasticity of the epithelial to mesenchymal transition induced by Von Hippel-Lindau inactivation in renal cell carcinomas.
    Pantuck AJ; An J; Liu H; Rettig MB
    Cancer Res; 2010 Jan; 70(2):752-61. PubMed ID: 20068166
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney.
    Beroukhim R; Brunet JP; Di Napoli A; Mertz KD; Seeley A; Pires MM; Linhart D; Worrell RA; Moch H; Rubin MA; Sellers WR; Meyerson M; Linehan WM; Kaelin WG; Signoretti S
    Cancer Res; 2009 Jun; 69(11):4674-81. PubMed ID: 19470766
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein.
    Nakamura E; Abreu-e-Lima P; Awakura Y; Inoue T; Kamoto T; Ogawa O; Kotani H; Manabe T; Zhang GJ; Kondo K; Nosé V; Kaelin WG
    Am J Pathol; 2006 Feb; 168(2):574-84. PubMed ID: 16436671
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
    Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Tumor suppressor gene VHL, hypoxia inducible factor, and renal cell carcinoma].
    Zhang YT; Chen N; Zeng H; Zhou Q
    Zhonghua Bing Li Xue Za Zhi; 2006 Sep; 35(9):562-4. PubMed ID: 17134554
    [No Abstract]   [Full Text] [Related]  

  • 35. Mutational analysis of the von hippel lindau gene in clear cell renal carcinomas from tuberous sclerosis complex patients.
    Duffy K; Al-Saleem T; Karbowniczek M; Ewalt D; Prowse AH; Henske EP
    Mod Pathol; 2002 Mar; 15(3):205-10. PubMed ID: 11904337
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Von Hippel-Lindau syndrome: molecular mechanisms of the disease.
    Calzada MJ
    Clin Transl Oncol; 2010 Mar; 12(3):160-5. PubMed ID: 20231120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor.
    Baba M; Hirai S; Yamada-Okabe H; Hamada K; Tabuchi H; Kobayashi K; Kondo K; Yoshida M; Yamashita A; Kishida T; Nakaigawa N; Nagashima Y; Kubota Y; Yao M; Ohno S
    Oncogene; 2003 May; 22(18):2728-38. PubMed ID: 12743597
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elongin C (ELOC/TCEB1)-associated von Hippel-Lindau disease.
    Andreou A; Yngvadottir B; Bassaganyas L; Clark G; Martin E; Whitworth J; Cornish AJ; ; Houlston RS; Rich P; Egan C; Hodgson SV; Warren AY; Snape K; Maher ER
    Hum Mol Genet; 2022 Aug; 31(16):2728-2737. PubMed ID: 35323939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. VHL gene mutations and their effects on hypoxia inducible factor HIFα: identification of potential driver and passenger mutations.
    Rechsteiner MP; von Teichman A; Nowicka A; Sulser T; Schraml P; Moch H
    Cancer Res; 2011 Aug; 71(16):5500-11. PubMed ID: 21715564
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Von Hippel-Lindau disease.
    Kaelin WG
    Annu Rev Pathol; 2007; 2():145-73. PubMed ID: 18039096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.